← Evidence map

ArticleLife (Basel, Switzerland)2026

Real-World Experience with Brolucizumab in Treatment-Naïve nAMD with Low Baseline Visual Acuity: Short-Term Outcomes from a Prospective Single-Institution Study.

Arsim Hajdari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Real-World Experience with Brolucizumab in Treatment-Naïve nAMD with Low Baseline Visual Acuity: Short-Term Outcomes from a Prospective Single-Institution Study. | OpenQuestion